This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Akili Dividende

Dividende contrôle des critères 0/6

Akili does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.0%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$0.62
Prévision de rendement du dividende	0%

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Akili surges 21% as Singapore investment firms take joint stake

Aug 26

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if AKLI's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if AKLI's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Akili Rendement des dividendes par rapport au marché

Comment le rendement du dividende de AKLI se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (AKLI)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Healthcare Services)	1.0%
Analyste prévisionnel (AKLI) (jusqu'à 3 ans)	0%

Dividende notable: Unable to evaluate AKLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate AKLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate AKLI's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as AKLI has not reported any payouts.

This company has been acquired

Akili Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Report Q1, 2024 Results on May 14, 2024

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

New major risk - Share price stability

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Price target increased by 25% to US$5.00

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akili Receives Non-Compliance Notice from Nasdaq

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

Price target decreased by 25% to US$3.00

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%

Consensus revenue estimates decrease by 44%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

Consensus revenue estimates increase by 32%, EPS downgraded

Price target decreased by 8.3% to US$3.44

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 26%, EPS upgraded

Full year 2022 earnings released: US$0.10 loss per share (vs US$106 loss in FY 2021)

Akili, Inc. announces Pivotal Trial of Endeavorrx in Adolescents with Adhd Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. Announces the Appointment of Scott Kollins, Ph.D., as Chief Medical Officer, Effective December 1, 2022

Consensus forecasts updated

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$35.91 (vs US$15.61 loss in 3Q 2021)

Akili, Inc. Announces Board Changes

Akili surges 21% as Singapore investment firms take joint stake

Second quarter 2022 earnings released

No independent directors

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés